Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study

医学 重症肌无力 耐受性 不利影响 抗原 嵌合抗原受体 自身抗体 免疫疗法 内科学 胃肠病学 免疫学 抗体 癌症
作者
Volkan Granit,Michael Benatar,Metin Kurtoğlu,Miloš D. Miljković,Nizar Chahin,Gregory Sahagian,Marc H. Feinberg,Adam Slansky,Tuan Vu,Christopher M. Jewell,Michael S. Singer,Murat V. Kalayoglu,James F. Howard,Tahseen Mozaffar,Volkan Granit,Michael Benatar,Tahseen Mozaffar,Nizar Chahin,James F. Howard,Adam D. Slansky
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:22 (7): 578-590 被引量:128
标识
DOI:10.1016/s1474-4422(23)00194-1
摘要

Background Chimeric antigen receptor (CAR) T cells are highly effective in treating haematological malignancies, but associated toxicities and the need for lymphodepletion limit their use in people with autoimmune disease. To explore the use of CAR T cells for the treatment of people with autoimmune disease, and to improve their safety, we engineered them with RNA (rCAR-T)—rather than the conventional DNA approach—to target B-cell maturation antigen (BCMA) expressed on plasma cells. To test the suitability of our approach, we used rCAR-T to treat individuals with myasthenia gravis, a prototypical autoantibody disease mediated partly by pathogenic plasma cells. Methods MG-001 was a prospective, multicentre, open-label, phase 1b/2a study of Descartes-08, an autologous anti-BCMA rCAR-T therapy, in adults (ie, aged ≥18 years) with generalised myasthenia gravis and a Myasthenia Gravis Activities of Daily Living (MG-ADL) score of 6 or higher. The study was done at eight sites (ie, academic medical centres or community neurology clinics) in the USA. Lymphodepletion chemotherapy was not used. In part 1 (phase 1b), participants with Myasthenia Gravis Foundation of America (MGFA) disease class III–IV generalised myasthenia gravis received three ascending doses of Descartes-08 to determine a maximum tolerated dose. In part 2 (phase 2a), participants with generalised myasthenia gravis with MGFA disease class II–IV received six doses at the maximum tolerated dose in an outpatient setting. The primary objective was to establish safety and tolerability of Descartes-08; secondary objectives were to assess myasthenia gravis disease severity and biomarkers in participants who received Descartes-08. This trial is registered with clinicaltrials.gov, NCT04146051. Findings We recruited 16 individuals for screening between Jan 7, 2020 and Aug 3, 2022. 14 participants were enrolled (n=3 in part 1, n=11 in part 2). Ten participants were women and four were men. Two individuals did not qualify due to low baseline MG-ADL score (n=1) or lack of generalised disease (n=1). Median follow-up in part 2 was 5 months (range 3–9 months). There was no dose-limiting toxicity, cytokine release syndrome, or neurotoxicity. Common adverse events were headache (six of 14 participants), nausea (five of 14), vomiting (three of 14), and fever (four of 14), which resolved within 24 h of infusion. Fevers were not associated with increased markers of cytokine release syndrome (IL-6, IL-2, and TNF). Mean improvements from baseline to week 12 were –6 (95% CI –9 to –3) for MG-ADL score, –7 (–11 to –3) for Quantitative Myasthenia Gravis score, –14 (–19 to –9) for Myasthenia Gravis Composite score, and –9 (–15 to –3) for Myasthenia Gravis Quality of Life 15-revised score. Interpretation In this first study of an rCAR-T therapy in individuals with an autoimmune disease, Descartes-08 appeared to be safe and was well tolerated. Descartes-08 infusions were followed by clinically meaningful decreases on myasthenia gravis severity scales at up to 9 months of follow-up. rCAR-T therapy warrants further investigation as a potential new treatment approach for individuals with myasthenia gravis and other autoimmune diseases. Funding Cartesian Therapeutics and National Institute of Neurological Disorders and Stroke of the National Institutes of Health.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
完美世界应助bfs采纳,获得10
1秒前
橘子sungua完成签到,获得积分10
2秒前
111完成签到,获得积分10
2秒前
4秒前
6秒前
7秒前
可乐加冰完成签到,获得积分10
7秒前
David驳回了Ant应助
7秒前
8秒前
9秒前
量子星尘发布了新的文献求助10
10秒前
思源应助果粒多采纳,获得10
10秒前
11秒前
好滴捏发布了新的文献求助10
12秒前
bfs发布了新的文献求助10
13秒前
WN发布了新的文献求助10
14秒前
14秒前
慕青应助小白采纳,获得10
15秒前
AAACharlie发布了新的文献求助10
15秒前
热情的达发布了新的文献求助10
15秒前
orixero应助lucky李采纳,获得10
16秒前
16秒前
momo发布了新的文献求助10
17秒前
17秒前
18秒前
guo完成签到,获得积分10
19秒前
可期完成签到,获得积分10
20秒前
21秒前
wsj发布了新的文献求助10
21秒前
果粒多发布了新的文献求助10
22秒前
科目三应助ylq采纳,获得30
23秒前
liupc2019发布了新的文献求助20
24秒前
张雯思发布了新的文献求助10
27秒前
希望天下0贩的0应助momo采纳,获得10
27秒前
28秒前
29秒前
梦华完成签到 ,获得积分10
30秒前
31秒前
ylq发布了新的文献求助30
35秒前
okface关注了科研通微信公众号
35秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989297
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253893
捐赠科研通 3270097
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809158